ZVRA earnings: real EPS beat/miss history, analyst consensus Buy, P/E 5.57. Updated 2026-07-23.
Zevra Therapeutics (ZVRA) Research Hub
Zevra Therapeutics (ZVRA) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 12.01 USD (-0.25%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 5.57, market cap 0.72B. This hub links to the full technical, earnings and options research available for ZVRA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 12.01 USD (-0.25%) |
| 52-week range | 9.1 USD – 14.96 USD |
| Trend regime | Range |
| 14-day RSI | 55.2 (Bullish) |
| Trailing P/E | 5.57 |
| Market cap | 0.72B |
| Dividend yield | 0.00% |
Available research for ZVRA
Covered Call on ZVRA: how it works, illustrative setup around the real 12.01 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ZVRA: how it works, illustrative setup around the real 12.01 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ZVRA: how it works, illustrative setup around the real 12.01 USD price, max profit/loss, breakeven and when to use it. Educational.
ZVRA technical analysis: range, last 12.01 USD, RSI 55.2, 52w range 9.1 USD–14.96 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is ZVRA in?
Zevra Therapeutics (ZVRA) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ZVRA in an uptrend or downtrend?
As of 2026-09-11, ZVRA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ZVRA's trailing P/E ratio?
ZVRA's trailing P/E is 5.57, with a market cap of 0.72B. See the earnings research page for full valuation detail.